ResultsIQ

ResultsIQ › Latest results › PCBL Chemical Limited

PCBL Chemical Limited Q1 FY26 earnings call summary

NSE: PCBL · BSE: 506590

Earnings call of 23 Jul 2025, summarised by AI from the filing.

PCBL Chemical Q1 FY26: revenue ₹2,114 cr, EBITDA ₹325 cr, PAT ₹94 cr; maintains Aquapharm ₹300 cr EBITDA guidance.

Key takeaways

  1. Aquapharm guidance Management maintains ₹300 cr EBITDA guidance for the current year.
  2. Power business Record power generation 215 MUs and external sales 132 MUs, adding ₹25 cr incremental EBIT QoQ.
  3. Capacity expansion Tamil Nadu phase 1 trial runs commenced; phase 2 to be commissioned by end of this financial year.
  4. Market risk Dumping into Indian market remains elevated, impacting pricing.

Original filing on BSE

PCBL Chemical Limited Q1 FY27 results

As filed: Revenue ₹2,473 cr (+17% year on year), EBITDA ₹396 cr (+24% year on year), PAT ₹155 cr (+65% year on year), EBITDA margin 16.0% (+95 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹2,066 cr (−1% year on year), EBITDA ₹243 cr (−18% year on year), PAT ₹40.2 cr (−60% year on year), EBITDA margin 11.8% (−246 bps). Score 28 of 100, Below trend. Revenue and EBITDA growth were below the company's own trend; profit growth was well below it. EBITDA margin fell 246 bps year on year. Share price after the results: −3.0% in 29 days (Nifty 500: −0.9%).
  • Q3 FY26: Revenue ₹1,846 cr (−8% year on year), EBITDA ₹215 cr (−33% year on year), PAT ₹2.0 cr (−75% year on year), EBITDA margin 11.6% (−424 bps). Score 4 of 100, Below trend. Revenue, EBITDA and profit before exceptional items growth were well below the company's own trend. EBITDA margin fell 424 bps year on year. Other income 161% of PBT. Tax rate 80%. Revenue fell 15% from last quarter. Share price after the results: +6.1% in 30 days (Nifty 500: −0.6%).
  • Q2 FY26: Revenue ₹2,164 cr (0% year on year), EBITDA ₹266 cr (−27% year on year), PAT ₹62.0 cr (−50% year on year), EBITDA margin 12.3% (−449 bps). Score 17 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 449 bps year on year. Profit fell 34% from last quarter. Share price after the results: −10.4% in 28 days (Nifty 500: +1.2%).
  • Q1 FY26: Revenue ₹2,114 cr (−1% year on year), EBITDA ₹318 cr (−11% year on year), PAT ₹94.0 cr (−20% year on year), EBITDA margin 15.0% (−166 bps). Score 20 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 166 bps year on year. Profit fell 6% from last quarter. Share price after the results: −8.5% in 30 days (Nifty 500: −1.4%).
  • Q4 FY25: Revenue ₹2,087 cr (+8% year on year), EBITDA ₹297 cr (−4% year on year), PAT ₹100 cr (−10% year on year), EBITDA margin 14.2% (−179 bps). Score 21 of 100, Below trend. Revenue and EBITDA growth were well below the company's own trend; profit growth was below it. EBITDA margin fell 179 bps year on year. Revenue rose ₹158 cr on a year ago, against ₹555 cr the year before. Share price after the results: +5.8% in 30 days (Nifty 500: +3.4%).
  • Q3 FY25: Revenue ₹2,010 cr (+21% year on year), EBITDA ₹319 cr (+14% year on year), PAT ₹93.0 cr (−37% year on year), EBITDA margin 15.9% (−97 bps). Score 31 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 97 bps year on year. Revenue fell 7% from last quarter. Revenue rose ₹353 cr on a year ago, more than the ₹294 cr it added the year before.
  • Q2 FY25: Revenue ₹2,163 cr (+45% year on year), EBITDA ₹363 cr (+53% year on year), PAT ₹123 cr (0% year on year), EBITDA margin 16.8% (+78 bps). Score 75 of 100, Above trend. EBITDA margin rose 78 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

PCBL Chemical Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.